Abstracts tagged "Treg cells"

Abstract Number: 1824 • ACR Convergence 2020
Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358
Christie Fanton¹, Richard Furie², Neha Dixit¹, Cat Haglund¹, Lin Lu¹, Suresh Siddhanti¹, Vishala Chindalore³, Robert Levin⁴, Isam Diab⁵, Brian Kotzin¹ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Division of Rheumatology, Northwell Health, Great Neck, NY, ³Pinnacle Research Group, Anniston, AL, ⁴Clinical Research of West Florida, Clearwater, FL, ⁵Paramount Medical Research and Consulting, Middleburg Heights, OH
Background/Purpose: Treg dysfunction and impaired IL-2 production have been implicated as key immunological defects in the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can…
Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt¹, Kevin Wei², Siobhan Case³, Margaret Chang¹, Ezra Cohen¹, Fatma Dedeoglu¹, Melissa Hazen¹, Jonathan Hausmann⁴, Olha Halyabar⁵, Erin Janssen⁵, Pui Lee⁶, Jeffrey Lo¹, Mindy Lo¹, Esra Meidan⁷, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel⁵, Talal Chatila¹, Peter Nigrovic⁸ and Lauren Henderson⁹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵Children's Hospital/Boston Medical Center, Boston, MA, ⁶1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁷Boston Children's Hospital, Somerville, MA, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁹Boston Children's Hospital, Watertown, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…
Abstract Number: 0851 • ACR Convergence 2020
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Peter Lipsky¹, Ronald van Vollenhoven², Thomas Dörner³, Victoria Werth⁴, Joan Merrill⁵, Richard Furie⁶, Milan Petronijevic⁷, Benito Velasco Zamora⁸, Maria Majdan⁹, Fedra Irazoque-Palazuelos¹⁰, Robert Terbrueggen¹¹, Nikolay Delev¹², Michael Weiswasser¹², Shimon Korish¹², Nataliya Agafonova¹², Mark Stern¹³, Sarah Hersey¹³, Ying Ye¹³, Allison Gaudy¹², Zhaohui Liu¹², Shaojun Tang¹³ and Peter Schafer¹², ¹RILITE Foundation, Charlottesville, VA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³DRFZ and Charité University Hospitals, Berlin, Germany, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷Military Medical Academy, Belgrade, Serbia, ⁸Instituto CER S.A., Buenos Aires, Argentina, ⁹Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ¹⁰Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ¹¹DxTerity Diagnostics Inc, Rancho Dominguez, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol-Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 89 • 2019 ACR/ARP Annual Meeting
Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Ximei Zhang¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State College of Medicine, Columbus, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Enhanced evidence supports that autoimmune diseases often result from an imbalance between regulatory T cells (Tregs) and interleukin-17-producing T helper (Th17) cells. However, under…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.